News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Onconova Therapeutics Inc. Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 American Society of Clinical Oncology Annual Meeting



5/16/2013 8:50:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that new safety and clinical activity data from its Phase 2 ONTARGET study will be presented on Saturday, June 1 during the American Society of Clinical Oncology Annual Meeting May 31 – June 4, 2013 in Chicago, Illinois. The ONTARGET trial is designed to evaluate oral rigosertib as a single agent in transfusion-dependent lower risk myelodysplastic syndrome patients.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES